The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis
Patients with multiple sclerosis (MS) are characterized by, among other symptoms, impaired functional capacity and walking difficulties. Polyunsaturated fatty acids (PUFAs) have been found to improve MS patients' clinical outcomes; however, their effect on other parameters associated with daily...
Gespeichert in:
| Veröffentlicht in: | Nutrients 2021-10, Vol.13 (10), p.3661 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | 3661 |
| container_title | Nutrients |
| container_volume | 13 |
| creator | Aristotelous, Panayiotis Stefanakis, Manos Pantzaris, Marios Pattichis, Constantinos S Calder, Philip C Patrikios, Ioannis S Sakkas, Giorgos K Giannaki, Christoforos D |
| description | Patients with multiple sclerosis (MS) are characterized by, among other symptoms, impaired functional capacity and walking difficulties. Polyunsaturated fatty acids (PUFAs) have been found to improve MS patients' clinical outcomes; however, their effect on other parameters associated with daily living activities need further investigation. The current study aimed to examine the effect of a 24-month supplementation with a cocktail dietary supplement formula, the Neuroaspis
PLP10, containing specific omega-3 and omega-6 PUFAs and specific antioxidant vitamins on gait and functional capacity parameters of patients with MS. Fifty-one relapsing-remitting MS (RRMS) patients with low disability scores (age: 38.4 ± 7.1 years; 30 female) were randomized 1:1 to receive either a 20 mL daily dose of the dietary formula containing a mixture of omega-3 and omega-6 PUFAs (12,150 mg), vitamin A (0.6 mg), vitamin E (22 mg), and γ-tocopherol (760 mg), the OMEGA group (
27; age: 39 ± 8.3 years), or 20 mL placebo containing virgin olive oil, the placebo group (
24; age: 37.8 ± 5.3 years). The mean ± SD (standard deviation) Expanded Disability Status Scale (EDSS) score for the placebo group was 2.36 and for the OMEGA group 2.22. All enrolled patients in the study were on Interferon-β treatment. Spatiotemporal gait parameters and gait deviation index (GDI) were assessed using a motion capture system. Functional capacity was examined using various functional tests such as the six-minute walk test (6MWT), two sit-to-stand tests (STS-5 and STS-60), and the Timed Up and Go test (TUG). Isometric handgrip strength was assessed by a dynamometer. Leg strength was assessed using an isokinetic dynamometer. All assessments were performed at baseline and at 12 and 24 months of supplementation. A total of 36 patients completed the study (18 from each group). Six patients from the placebo group and 9 patients from the OMEGA group dropped out from the study or were lost to follow-up. The dietary supplement significantly improved the single support time and the step and stride time (
< 0.05), both spatiotemporal gait parameters. In addition, while GDI of the placebo group decreased by about 10% at 24 months, it increased by about 4% in the OMEGA group (
< 0.05). Moreover, performance in the STS-60 test improved in the OMEGA group (
< 0.05) and there was a tendency for improvement in the 6MWT and TUG tests. Long-term supplementation with high dosages of omega-3 and omega-6 PUFAs (compared to pr |
| doi_str_mv | 10.3390/nu13103661 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2584785272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584785272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-df9386cf07deb940ccc16b08e1fd4519a2e3956c55a04829dbd999675e5ee5a63</originalsourceid><addsrcrecordid>eNpdkl9rFDEUxQdRbKl98QNIwBcRRjOTPzN5EcrSrUKlpa2-DneTO7spmcyYZNT9fH4x0-5aq3nJCfndw-FyiuJlRd8xpuh7P1esokzK6klxWNOmLqXk7OkjfVAcx3hL705DG8meFweMy5bnkcPi180GyWnfo06RjD25nlDb3mpyMeAaSkbAm72W5HJ029lHSHOAhIYsIaUtOdHWxHvuxCc7_rQGfCJfbYLB-mzqyRnYdA8sZ68z4sGRBUygbR6_hAADJgyRWJ9fyaLPWX7YtCFX6GCK1q_LKxxsSlmRz7NLdnJIrrXDMEYbXxTPenARj_f3UfFleXqz-FieX5x9Wpycl5pTmUrTK9ZK3dPG4EpxqrWu5Iq2WPWGi0pBjUwJqYUAyttamZVRSslGoEAUINlR8WHnO82rAY3OOQO4bgp2gLDtRrDdvz_ebrr1-L1rBaeKq2zwZm8Qxm8zxtQNNmp0DjyOc-xq0fKmFXVTZ_T1f-jtOIe8uB2V8zaSZurtjtJ5ETFg_xCmot1dPbq_9cjwq8fxH9A_ZWC_AeUWuQU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584451760</pqid></control><display><type>article</type><title>The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Aristotelous, Panayiotis ; Stefanakis, Manos ; Pantzaris, Marios ; Pattichis, Constantinos S ; Calder, Philip C ; Patrikios, Ioannis S ; Sakkas, Giorgos K ; Giannaki, Christoforos D</creator><creatorcontrib>Aristotelous, Panayiotis ; Stefanakis, Manos ; Pantzaris, Marios ; Pattichis, Constantinos S ; Calder, Philip C ; Patrikios, Ioannis S ; Sakkas, Giorgos K ; Giannaki, Christoforos D</creatorcontrib><description>Patients with multiple sclerosis (MS) are characterized by, among other symptoms, impaired functional capacity and walking difficulties. Polyunsaturated fatty acids (PUFAs) have been found to improve MS patients' clinical outcomes; however, their effect on other parameters associated with daily living activities need further investigation. The current study aimed to examine the effect of a 24-month supplementation with a cocktail dietary supplement formula, the Neuroaspis
PLP10, containing specific omega-3 and omega-6 PUFAs and specific antioxidant vitamins on gait and functional capacity parameters of patients with MS. Fifty-one relapsing-remitting MS (RRMS) patients with low disability scores (age: 38.4 ± 7.1 years; 30 female) were randomized 1:1 to receive either a 20 mL daily dose of the dietary formula containing a mixture of omega-3 and omega-6 PUFAs (12,150 mg), vitamin A (0.6 mg), vitamin E (22 mg), and γ-tocopherol (760 mg), the OMEGA group (
27; age: 39 ± 8.3 years), or 20 mL placebo containing virgin olive oil, the placebo group (
24; age: 37.8 ± 5.3 years). The mean ± SD (standard deviation) Expanded Disability Status Scale (EDSS) score for the placebo group was 2.36 and for the OMEGA group 2.22. All enrolled patients in the study were on Interferon-β treatment. Spatiotemporal gait parameters and gait deviation index (GDI) were assessed using a motion capture system. Functional capacity was examined using various functional tests such as the six-minute walk test (6MWT), two sit-to-stand tests (STS-5 and STS-60), and the Timed Up and Go test (TUG). Isometric handgrip strength was assessed by a dynamometer. Leg strength was assessed using an isokinetic dynamometer. All assessments were performed at baseline and at 12 and 24 months of supplementation. A total of 36 patients completed the study (18 from each group). Six patients from the placebo group and 9 patients from the OMEGA group dropped out from the study or were lost to follow-up. The dietary supplement significantly improved the single support time and the step and stride time (
< 0.05), both spatiotemporal gait parameters. In addition, while GDI of the placebo group decreased by about 10% at 24 months, it increased by about 4% in the OMEGA group (
< 0.05). Moreover, performance in the STS-60 test improved in the OMEGA group (
< 0.05) and there was a tendency for improvement in the 6MWT and TUG tests. Long-term supplementation with high dosages of omega-3 and omega-6 PUFAs (compared to previous published clinical studies using PUFAs) and specific antioxidant vitamins improved some functional capacity and gait parameters in RRMS patients.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu13103661</identifier><identifier>PMID: 34684661</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adult ; Ankle ; Antioxidants ; Antioxidants - pharmacology ; Body Composition - drug effects ; Clinical trials ; Dietary supplements ; Fatty acids ; Fatty Acids, Omega-3 - pharmacology ; Fatty Acids, Omega-6 - pharmacology ; Female ; Females ; Functional testing ; Gait ; Gait - drug effects ; Gait - physiology ; Gait recognition ; Hand Strength ; Humans ; Interferon ; Isometric ; Knee - physiopathology ; Male ; Motion capture ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - physiopathology ; Muscle function ; Nervous system ; Olive oil ; Patients ; Pharmacists ; Placebos ; Polyunsaturated fatty acids ; Time Factors ; Tocopherol ; Vitamin A ; Vitamin E ; Vitamins ; Vitamins - pharmacology ; β-Interferon</subject><ispartof>Nutrients, 2021-10, Vol.13 (10), p.3661</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-df9386cf07deb940ccc16b08e1fd4519a2e3956c55a04829dbd999675e5ee5a63</citedby><cites>FETCH-LOGICAL-c406t-df9386cf07deb940ccc16b08e1fd4519a2e3956c55a04829dbd999675e5ee5a63</cites><orcidid>0000-0003-2937-384X ; 0000-0003-1271-8151 ; 0000-0002-1280-6058 ; 0000-0002-6038-710X ; 0000-0003-0029-1189 ; 0000-0002-2462-995X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540949/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540949/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34684661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aristotelous, Panayiotis</creatorcontrib><creatorcontrib>Stefanakis, Manos</creatorcontrib><creatorcontrib>Pantzaris, Marios</creatorcontrib><creatorcontrib>Pattichis, Constantinos S</creatorcontrib><creatorcontrib>Calder, Philip C</creatorcontrib><creatorcontrib>Patrikios, Ioannis S</creatorcontrib><creatorcontrib>Sakkas, Giorgos K</creatorcontrib><creatorcontrib>Giannaki, Christoforos D</creatorcontrib><title>The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis</title><title>Nutrients</title><addtitle>Nutrients</addtitle><description>Patients with multiple sclerosis (MS) are characterized by, among other symptoms, impaired functional capacity and walking difficulties. Polyunsaturated fatty acids (PUFAs) have been found to improve MS patients' clinical outcomes; however, their effect on other parameters associated with daily living activities need further investigation. The current study aimed to examine the effect of a 24-month supplementation with a cocktail dietary supplement formula, the Neuroaspis
PLP10, containing specific omega-3 and omega-6 PUFAs and specific antioxidant vitamins on gait and functional capacity parameters of patients with MS. Fifty-one relapsing-remitting MS (RRMS) patients with low disability scores (age: 38.4 ± 7.1 years; 30 female) were randomized 1:1 to receive either a 20 mL daily dose of the dietary formula containing a mixture of omega-3 and omega-6 PUFAs (12,150 mg), vitamin A (0.6 mg), vitamin E (22 mg), and γ-tocopherol (760 mg), the OMEGA group (
27; age: 39 ± 8.3 years), or 20 mL placebo containing virgin olive oil, the placebo group (
24; age: 37.8 ± 5.3 years). The mean ± SD (standard deviation) Expanded Disability Status Scale (EDSS) score for the placebo group was 2.36 and for the OMEGA group 2.22. All enrolled patients in the study were on Interferon-β treatment. Spatiotemporal gait parameters and gait deviation index (GDI) were assessed using a motion capture system. Functional capacity was examined using various functional tests such as the six-minute walk test (6MWT), two sit-to-stand tests (STS-5 and STS-60), and the Timed Up and Go test (TUG). Isometric handgrip strength was assessed by a dynamometer. Leg strength was assessed using an isokinetic dynamometer. All assessments were performed at baseline and at 12 and 24 months of supplementation. A total of 36 patients completed the study (18 from each group). Six patients from the placebo group and 9 patients from the OMEGA group dropped out from the study or were lost to follow-up. The dietary supplement significantly improved the single support time and the step and stride time (
< 0.05), both spatiotemporal gait parameters. In addition, while GDI of the placebo group decreased by about 10% at 24 months, it increased by about 4% in the OMEGA group (
< 0.05). Moreover, performance in the STS-60 test improved in the OMEGA group (
< 0.05) and there was a tendency for improvement in the 6MWT and TUG tests. Long-term supplementation with high dosages of omega-3 and omega-6 PUFAs (compared to previous published clinical studies using PUFAs) and specific antioxidant vitamins improved some functional capacity and gait parameters in RRMS patients.</description><subject>Adult</subject><subject>Ankle</subject><subject>Antioxidants</subject><subject>Antioxidants - pharmacology</subject><subject>Body Composition - drug effects</subject><subject>Clinical trials</subject><subject>Dietary supplements</subject><subject>Fatty acids</subject><subject>Fatty Acids, Omega-3 - pharmacology</subject><subject>Fatty Acids, Omega-6 - pharmacology</subject><subject>Female</subject><subject>Females</subject><subject>Functional testing</subject><subject>Gait</subject><subject>Gait - drug effects</subject><subject>Gait - physiology</subject><subject>Gait recognition</subject><subject>Hand Strength</subject><subject>Humans</subject><subject>Interferon</subject><subject>Isometric</subject><subject>Knee - physiopathology</subject><subject>Male</subject><subject>Motion capture</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - physiopathology</subject><subject>Muscle function</subject><subject>Nervous system</subject><subject>Olive oil</subject><subject>Patients</subject><subject>Pharmacists</subject><subject>Placebos</subject><subject>Polyunsaturated fatty acids</subject><subject>Time Factors</subject><subject>Tocopherol</subject><subject>Vitamin A</subject><subject>Vitamin E</subject><subject>Vitamins</subject><subject>Vitamins - pharmacology</subject><subject>β-Interferon</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkl9rFDEUxQdRbKl98QNIwBcRRjOTPzN5EcrSrUKlpa2-DneTO7spmcyYZNT9fH4x0-5aq3nJCfndw-FyiuJlRd8xpuh7P1esokzK6klxWNOmLqXk7OkjfVAcx3hL705DG8meFweMy5bnkcPi180GyWnfo06RjD25nlDb3mpyMeAaSkbAm72W5HJ029lHSHOAhIYsIaUtOdHWxHvuxCc7_rQGfCJfbYLB-mzqyRnYdA8sZ68z4sGRBUygbR6_hAADJgyRWJ9fyaLPWX7YtCFX6GCK1q_LKxxsSlmRz7NLdnJIrrXDMEYbXxTPenARj_f3UfFleXqz-FieX5x9Wpycl5pTmUrTK9ZK3dPG4EpxqrWu5Iq2WPWGi0pBjUwJqYUAyttamZVRSslGoEAUINlR8WHnO82rAY3OOQO4bgp2gLDtRrDdvz_ebrr1-L1rBaeKq2zwZm8Qxm8zxtQNNmp0DjyOc-xq0fKmFXVTZ_T1f-jtOIe8uB2V8zaSZurtjtJ5ETFg_xCmot1dPbq_9cjwq8fxH9A_ZWC_AeUWuQU</recordid><startdate>20211019</startdate><enddate>20211019</enddate><creator>Aristotelous, Panayiotis</creator><creator>Stefanakis, Manos</creator><creator>Pantzaris, Marios</creator><creator>Pattichis, Constantinos S</creator><creator>Calder, Philip C</creator><creator>Patrikios, Ioannis S</creator><creator>Sakkas, Giorgos K</creator><creator>Giannaki, Christoforos D</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2937-384X</orcidid><orcidid>https://orcid.org/0000-0003-1271-8151</orcidid><orcidid>https://orcid.org/0000-0002-1280-6058</orcidid><orcidid>https://orcid.org/0000-0002-6038-710X</orcidid><orcidid>https://orcid.org/0000-0003-0029-1189</orcidid><orcidid>https://orcid.org/0000-0002-2462-995X</orcidid></search><sort><creationdate>20211019</creationdate><title>The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis</title><author>Aristotelous, Panayiotis ; Stefanakis, Manos ; Pantzaris, Marios ; Pattichis, Constantinos S ; Calder, Philip C ; Patrikios, Ioannis S ; Sakkas, Giorgos K ; Giannaki, Christoforos D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-df9386cf07deb940ccc16b08e1fd4519a2e3956c55a04829dbd999675e5ee5a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Ankle</topic><topic>Antioxidants</topic><topic>Antioxidants - pharmacology</topic><topic>Body Composition - drug effects</topic><topic>Clinical trials</topic><topic>Dietary supplements</topic><topic>Fatty acids</topic><topic>Fatty Acids, Omega-3 - pharmacology</topic><topic>Fatty Acids, Omega-6 - pharmacology</topic><topic>Female</topic><topic>Females</topic><topic>Functional testing</topic><topic>Gait</topic><topic>Gait - drug effects</topic><topic>Gait - physiology</topic><topic>Gait recognition</topic><topic>Hand Strength</topic><topic>Humans</topic><topic>Interferon</topic><topic>Isometric</topic><topic>Knee - physiopathology</topic><topic>Male</topic><topic>Motion capture</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - physiopathology</topic><topic>Muscle function</topic><topic>Nervous system</topic><topic>Olive oil</topic><topic>Patients</topic><topic>Pharmacists</topic><topic>Placebos</topic><topic>Polyunsaturated fatty acids</topic><topic>Time Factors</topic><topic>Tocopherol</topic><topic>Vitamin A</topic><topic>Vitamin E</topic><topic>Vitamins</topic><topic>Vitamins - pharmacology</topic><topic>β-Interferon</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aristotelous, Panayiotis</creatorcontrib><creatorcontrib>Stefanakis, Manos</creatorcontrib><creatorcontrib>Pantzaris, Marios</creatorcontrib><creatorcontrib>Pattichis, Constantinos S</creatorcontrib><creatorcontrib>Calder, Philip C</creatorcontrib><creatorcontrib>Patrikios, Ioannis S</creatorcontrib><creatorcontrib>Sakkas, Giorgos K</creatorcontrib><creatorcontrib>Giannaki, Christoforos D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aristotelous, Panayiotis</au><au>Stefanakis, Manos</au><au>Pantzaris, Marios</au><au>Pattichis, Constantinos S</au><au>Calder, Philip C</au><au>Patrikios, Ioannis S</au><au>Sakkas, Giorgos K</au><au>Giannaki, Christoforos D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis</atitle><jtitle>Nutrients</jtitle><addtitle>Nutrients</addtitle><date>2021-10-19</date><risdate>2021</risdate><volume>13</volume><issue>10</issue><spage>3661</spage><pages>3661-</pages><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Patients with multiple sclerosis (MS) are characterized by, among other symptoms, impaired functional capacity and walking difficulties. Polyunsaturated fatty acids (PUFAs) have been found to improve MS patients' clinical outcomes; however, their effect on other parameters associated with daily living activities need further investigation. The current study aimed to examine the effect of a 24-month supplementation with a cocktail dietary supplement formula, the Neuroaspis
PLP10, containing specific omega-3 and omega-6 PUFAs and specific antioxidant vitamins on gait and functional capacity parameters of patients with MS. Fifty-one relapsing-remitting MS (RRMS) patients with low disability scores (age: 38.4 ± 7.1 years; 30 female) were randomized 1:1 to receive either a 20 mL daily dose of the dietary formula containing a mixture of omega-3 and omega-6 PUFAs (12,150 mg), vitamin A (0.6 mg), vitamin E (22 mg), and γ-tocopherol (760 mg), the OMEGA group (
27; age: 39 ± 8.3 years), or 20 mL placebo containing virgin olive oil, the placebo group (
24; age: 37.8 ± 5.3 years). The mean ± SD (standard deviation) Expanded Disability Status Scale (EDSS) score for the placebo group was 2.36 and for the OMEGA group 2.22. All enrolled patients in the study were on Interferon-β treatment. Spatiotemporal gait parameters and gait deviation index (GDI) were assessed using a motion capture system. Functional capacity was examined using various functional tests such as the six-minute walk test (6MWT), two sit-to-stand tests (STS-5 and STS-60), and the Timed Up and Go test (TUG). Isometric handgrip strength was assessed by a dynamometer. Leg strength was assessed using an isokinetic dynamometer. All assessments were performed at baseline and at 12 and 24 months of supplementation. A total of 36 patients completed the study (18 from each group). Six patients from the placebo group and 9 patients from the OMEGA group dropped out from the study or were lost to follow-up. The dietary supplement significantly improved the single support time and the step and stride time (
< 0.05), both spatiotemporal gait parameters. In addition, while GDI of the placebo group decreased by about 10% at 24 months, it increased by about 4% in the OMEGA group (
< 0.05). Moreover, performance in the STS-60 test improved in the OMEGA group (
< 0.05) and there was a tendency for improvement in the 6MWT and TUG tests. Long-term supplementation with high dosages of omega-3 and omega-6 PUFAs (compared to previous published clinical studies using PUFAs) and specific antioxidant vitamins improved some functional capacity and gait parameters in RRMS patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34684661</pmid><doi>10.3390/nu13103661</doi><orcidid>https://orcid.org/0000-0003-2937-384X</orcidid><orcidid>https://orcid.org/0000-0003-1271-8151</orcidid><orcidid>https://orcid.org/0000-0002-1280-6058</orcidid><orcidid>https://orcid.org/0000-0002-6038-710X</orcidid><orcidid>https://orcid.org/0000-0003-0029-1189</orcidid><orcidid>https://orcid.org/0000-0002-2462-995X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6643 |
| ispartof | Nutrients, 2021-10, Vol.13 (10), p.3661 |
| issn | 2072-6643 2072-6643 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2584785272 |
| source | MEDLINE; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Ankle Antioxidants Antioxidants - pharmacology Body Composition - drug effects Clinical trials Dietary supplements Fatty acids Fatty Acids, Omega-3 - pharmacology Fatty Acids, Omega-6 - pharmacology Female Females Functional testing Gait Gait - drug effects Gait - physiology Gait recognition Hand Strength Humans Interferon Isometric Knee - physiopathology Male Motion capture Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - physiopathology Muscle function Nervous system Olive oil Patients Pharmacists Placebos Polyunsaturated fatty acids Time Factors Tocopherol Vitamin A Vitamin E Vitamins Vitamins - pharmacology β-Interferon |
| title | The Effects of Specific Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins on Gait and Functional Capacity Parameters in Patients with Relapsing-Remitting Multiple Sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A02%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20of%20Specific%20Omega-3%20and%20Omega-6%20Polyunsaturated%20Fatty%20Acids%20and%20Antioxidant%20Vitamins%20on%20Gait%20and%20Functional%20Capacity%20Parameters%20in%20Patients%20with%20Relapsing-Remitting%20Multiple%20Sclerosis&rft.jtitle=Nutrients&rft.au=Aristotelous,%20Panayiotis&rft.date=2021-10-19&rft.volume=13&rft.issue=10&rft.spage=3661&rft.pages=3661-&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu13103661&rft_dat=%3Cproquest_pubme%3E2584785272%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584451760&rft_id=info:pmid/34684661&rfr_iscdi=true |